Stock Track | Vir Biotechnology (VIR) Soars 5.03% as Analysts Maintain Buy Ratings

Stock Track

18 hours ago

Vir Biotechnology, Inc. (VIR) shares are soaring 5.03% in intraday trading on Tuesday, buoyed by positive analyst ratings from major financial institutions. The biotechnology company's stock is experiencing significant upward momentum as investors react to the latest Wall Street assessments.

Morgan Stanley has reiterated its Buy rating on Vir Biotechnology, setting a price target of $20.00. This bullish stance from a leading investment bank suggests strong confidence in the company's future prospects. Additionally, TD Cowen has also maintained its Buy rating on VIR, further reinforcing the positive sentiment surrounding the stock.

These optimistic analyst views come at a crucial time for Vir Biotechnology, potentially indicating the market's growing recognition of the company's value proposition in the competitive biotech sector. As investors digest these recommendations, the stock's surge reflects increased buying interest and possibly renewed confidence in Vir's pipeline and strategic direction.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1127241931"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1127241931\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1127241931?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 03:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127241931","market":"sg","top_or_hot":-1,"title":"Stock Track | Vir Biotechnology (VIR) Soars 5.03% as Analysts Maintain Buy Ratings","media":"Stock Track","content":"<p>Vir Biotechnology, Inc. (VIR) shares are soaring 5.03% in intraday trading on Tuesday, buoyed by positive analyst ratings from major financial institutions. The biotechnology company's stock is experiencing significant upward momentum as investors react to the latest Wall Street assessments.</p>\n\n<p>Morgan Stanley has reiterated its Buy rating on Vir Biotechnology, setting a price target of $20.00. This bullish stance from a leading investment bank suggests strong confidence in the company's future prospects. Additionally, TD Cowen has also maintained its Buy rating on VIR, further reinforcing the positive sentiment surrounding the stock.</p>\n\n<p>These optimistic analyst views come at a crucial time for Vir Biotechnology, potentially indicating the market's growing recognition of the company's value proposition in the competitive biotech sector. As investors digest these recommendations, the stock's surge reflects increased buying interest and possibly renewed confidence in Vir's pipeline and strategic direction.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Vir Biotechnology (VIR) Soars 5.03% as Analysts Maintain Buy Ratings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Vir Biotechnology (VIR) Soars 5.03% as Analysts Maintain Buy Ratings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-12 03:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vir Biotechnology, Inc. (VIR) shares are soaring 5.03% in intraday trading on Tuesday, buoyed by positive analyst ratings from major financial institutions. The biotechnology company's stock is experiencing significant upward momentum as investors react to the latest Wall Street assessments.</p>\n\n<p>Morgan Stanley has reiterated its Buy rating on Vir Biotechnology, setting a price target of $20.00. This bullish stance from a leading investment bank suggests strong confidence in the company's future prospects. Additionally, TD Cowen has also maintained its Buy rating on VIR, further reinforcing the positive sentiment surrounding the stock.</p>\n\n<p>These optimistic analyst views come at a crucial time for Vir Biotechnology, potentially indicating the market's growing recognition of the company's value proposition in the competitive biotech sector. As investors digest these recommendations, the stock's surge reflects increased buying interest and possibly renewed confidence in Vir's pipeline and strategic direction.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VIR","symbol_name":"Vir Biotechnology, Inc.","start_time":0,"source_url":"","article_id":"1127241931","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127241931","pubTimestamp":1762888830,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Vir Biotechnology, Inc. (VIR) shares are soaring 5.03% in intraday trading on Tuesday, buoyed by positive analyst ratings from major financial institutions. The biotechnology company's stock is...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VIR":"Vir Biotechnology, Inc."},"translate_title":"个股追踪|Vir Biotechnology(VIR)大涨5.03%分析师维持买入评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":1},"content_text":"Vir Biotechnology, Inc. (VIR) shares are soaring 5.03% in intraday trading on Tuesday, buoyed by positive analyst ratings from major financial institutions. The biotechnology company's stock is experiencing significant upward momentum as investors react to the latest Wall Street assessments.\nMorgan Stanley has reiterated its Buy rating on Vir Biotechnology, setting a price target of $20.00. This bullish stance from a leading investment bank suggests strong confidence in the company's future prospects. Additionally, TD Cowen has also maintained its Buy rating on VIR, further reinforcing the positive sentiment surrounding the stock.\nThese optimistic analyst views come at a crucial time for Vir Biotechnology, potentially indicating the market's growing recognition of the company's value proposition in the competitive biotech sector. As investors digest these recommendations, the stock's surge reflects increased buying interest and possibly renewed confidence in Vir's pipeline and strategic direction.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}